Oncimmune higher as it presents positive trial data at lung cancer conference

The diagnostics firm had presented its data at the World Conference for Lung Cancer in Barcelona

Oncimmune - Oncimmune higher as it presents positive trial data at lung cancer conference

Oncimmune Holdings PLC (LON:ONC) shares were higher on Monday after positive trial data from its EarlyCDT Lung test were presented at the World Conference for Lung Cancer in Barcelona.

Results from the successful ECLS study of 12,209 Scottish patients were first released in June.

Oncimmune said the presentation of detailed information at the Barcelona gathering was an “important validation” of its technology, with the next step being a larger population-based evaluation of up to 200,000 patients.

"We are thrilled that the ECLS trial has demonstrated so clearly the potential of our EarlyCDT technology platform to transform the way cancer is diagnosed”, said Adam Hill, Oncimmune’s chief executive.

He added that the firm would work with Scottish health authorities to roll out the test more widely while also testing the technology on other forms of cancer including liver, ovarian, breast and prostate.

In mid-morning trading, the shares were up 5.5% at 96p.

Quick facts: Oncimmune

Price: 131 GBX

Market: AIM
Market Cap: £83.2 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...



Oncimmune CEO says they're seeing 'significant interest' in its EarlyCDT...

Oncimmune Holdings PLC's (LON:ONC) Adam Hill tells Proactive the next 18 months are expected to create substantial revenues within the EarlyCDT lung cancer test business while the pipeline of contracts within the ImmunoINSIGHTS services business is building. In a trading update covering the...

on 5/6/20

2 min read